Product image of Metalyse (Tenecteplase) supplied by GNH India

Metalyse

Active Ingredient:
Tenecteplase
Origin:
EU

Metalyse (Tenecteplase)

Tenecteplase, the active ingredient in Metalyse, is a thrombolytic agent presented as a powder for solution for injection for intravenous use. It facilitates rapid clot dissolution in the coronary arteries of adults experiencing an acute ST‑segment elevation myocardial infarction (STEMI), helping to restore blood flow and limit heart muscle damage. The drug is supplied in a sterile lyophilized form that is reconstituted immediately before administration under aseptic conditions.

GNH India supplies Metalyse as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Boehringer Ingelheim International Gmbh

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

  • Metalyse (tenecteplase) is a thrombolytic agent used in the management of acute coronary artery occlusion.
  • Acute myocardial infarction (STEMI): rapid reperfusion to restore coronary blood flow and limit myocardial injury.

How It Works

  • Tenecteplase is a recombinant tissue‑type plasminogen activator that binds to fibrin within a thrombus and converts circulating plasminogen to plasmin. The generated plasmin degrades fibrin strands, leading to clot dissolution. Its high fibrin specificity and prolonged plasma half‑life allow a single bolus intravenous administration, providing swift reperfusion of occluded coronary vessels.

Side Effects

Common Side Effects

  • Bleeding at the injection site: mild to moderate bruising or hematoma.
  • Nausea: transient gastrointestinal discomfort.
  • Headache: mild to moderate intensity.
  • Hypotension: temporary drop in blood pressure.
  • Fever: low‑grade temperature elevation.
  • Dizziness: transient light‑headedness.

Serious or Rare Side Effects

  • Intracranial hemorrhage: potentially life‑threatening bleeding in the brain.
  • Severe allergic reaction: anaphylaxis or angioedema.
  • Myocardial rupture: rare tearing of heart muscle.
  • Disseminated intravascular coagulation: abnormal clotting throughout the body.
  • Severe hypotension: profound drop in blood pressure requiring intervention.
  • Pulmonary hemorrhage: bleeding within the lungs.

Precautions & Warnings

  • Metalyse should be used only after careful assessment of bleeding risk and contraindications.
  • Assess bleeding risk: evaluate recent surgery, trauma, or active hemorrhage.
  • Avoid in active internal bleeding: contraindicated when uncontrolled bleeding is present.
  • Use with caution in uncontrolled hypertension: high blood pressure increases hemorrhagic risk.
  • Monitor coagulation parameters during therapy: track PT/INR and aPTT as needed.
  • Contraindicated in known hypersensitivity to tenecteplase or its excipients.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Tenalyse may interact with several drug classes, requiring careful management.

Major Interactions (Avoid)

  • Other thrombolytic agents: additive risk of severe bleeding.
  • Therapeutic anticoagulants (heparin, low‑molecular‑weight heparin, warfarin): increased anticoagulant effect.
  • Full‑dose antiplatelet drugs (e.g., clopidogrel, aspirin): heightened bleeding tendency.

Moderate Interactions (Monitor Closely)

  • Non‑steroidal anti‑inflammatory drugs (NSAIDs): may amplify bleeding risk.
  • Selective serotonin reuptake inhibitors (SSRIs): potential platelet dysfunction.
  • Glycoprotein IIb/IIIa inhibitors: monitor for excessive bleeding.

Frequently Asked Questions

Metalyse is indicated for the rapid treatment of acute ST‑segment elevation myocardial infarction (STEMI) in adult patients. By dissolving the occluding coronary clot, it helps restore blood flow to the heart muscle and limits the extent of myocardial damage.

Tenecteplase is a recombinant tissue‑type plasminogen activator that binds to fibrin within a clot and converts plasminogen to plasmin. The resulting plasmin breaks down fibrin strands, leading to clot dissolution and reperfusion of the blocked coronary artery.

The dose of Metalyse is determined by the prescribing clinician based on the patient’s weight, clinical condition, and local guidelines. It is administered as a single intravenous bolus after reconstitution.

Safety of tenecteplase in pregnancy and lactation has not been established. It should be used only if the potential maternal benefit justifies the potential risk to the fetus or infant, and only under specialist supervision.

To order Metalyse, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and import documentation.

Both tenecteplase (Metalyse) and alteplase are recombinant tissue‑type plasminogen activators, but tenecteplase has higher fibrin specificity, a longer half‑life, and can be given as a single bolus, whereas alteplase requires an initial bolus followed by an infusion. These differences can simplify administration and may reduce infusion‑related complications.

Metalyse is supplied as a lyophilized powder for reconstitution. Store it at 2‑8 °C, protected from light, and do not freeze or shake the vial. Keep the product in its original packaging until ready for use to maintain stability.

After reconstituting the powder with the appropriate diluent, Metalyse is given as a single intravenous bolus injection over a few seconds. Administration should be performed by qualified healthcare personnel under aseptic conditions.

The most serious risks include intracranial hemorrhage, severe systemic bleeding, allergic reactions such as anaphylaxis, myocardial rupture, and disseminated intravascular coagulation. Prompt recognition and management of these events are essential.

Metalyse is contraindicated in patients with active internal bleeding, recent intracranial or in‑trunk surgery, known hypersensitivity to tenecteplase or its excipients, uncontrolled hypertension, and in those who have received another thrombolytic agent within the previous 24 hours.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Tenecteplase

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT